Literature DB >> 26956456

[Anterior segment findings with far-reaching consequences].

V Besgen1, P Seipelt2, Y Wenner3,4.   

Abstract

Mesh：

Year:  2016        PMID： 26956456     DOI： 10.1007/s00347-016-0232-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  13 in total

1.  X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease.

Authors:  D P Germain; K Benistan; L Angelova
Journal:  Rev Med Interne       Date:  2010-12       Impact factor: 0.728

2.  Disease manifestations and X inactivation in heterozygous females with Fabry disease.

Authors:  Esther M Maier; Stephanie Osterrieder; Catharina Whybra; Markus Ries; Andreas Gal; Michael Beck; Adelbert A Roscher; Ania C Muntau
Journal:  Acta Paediatr Suppl       Date:  2006-04

3.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

Review 4.  Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.

Authors:  Michael Beck
Journal:  Expert Opin Biol Ther       Date:  2009-02       Impact factor: 4.388

5.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

Review 6.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

Review 7.  Spotlight on agalsidase beta in Fabry disease.

Authors:  Gillian M Keating; Dene Simpson
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

8.  The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

Authors:  C Whybra; C Kampmann; F Krummenauer; M Ries; E Mengel; E Miebach; F Baehner; K Kim; M Bajbouj; A Schwarting; A Gal; M Beck
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

Review 9.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

10.  Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.

Authors:  Dominique P Germain; Joel Charrow; Robert J Desnick; Nathalie Guffon; Judy Kempf; Robin H Lachmann; Roberta Lemay; Gabor E Linthorst; Seymour Packman; C Ronald Scott; Stephen Waldek; David G Warnock; Neal J Weinreb; William R Wilcox
Journal:  J Med Genet       Date:  2015-03-20       Impact factor: 6.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.